Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 44.89% is 60% above its 5-year average of 28.12%, around the middle of its 5-year range (0.00%–100.00%).
22.76% below its 12-month average of 58.11%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
44.89%
GROSS MARGIN AVG TTM
58.11%
GROSS MARGIN AVG 3Y
37.74%
GROSS MARGIN AVG 5Y
28.12%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-22.76%
CURRENT VS 3Y AVG
+18.96%
CURRENT VS 5Y AVG
+59.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.32%
median of 777 covered companies
CURRENT VS SECTOR MEDIAN
+11.33%
vs the sector median at left
Rani Therapeutics Holdings, Inc.
Market Cap
$51.38M
Gross Margin
44.89%
TTM Avg
58.11%
3Y Avg
37.74%
5Y Avg
28.12%
Market Cap
$51.33M
Gross Margin
-262.66%
TTM Avg
-246.22%
3Y Avg
-188.06%
5Y Avg
-150.05%
Market Cap
$51.91M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$50.45M
Gross Margin
N/A
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$50.08M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | $51.38M | 44.89% | 58.11% | 37.74% | 28.12% |
| Envoy Medical, Inc. (COCH)vs › | $51.33M | -262.66% | -246.22% | -188.06% | -150.05% |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $51.91M | 0.00% | 0.00% | 0.00% | 0.00% |
| biote Corp. (BTMD)vs › | $51.61M | 71.46% | 70.99% | 69.42% | 67.35% |
| Celularity Inc. (CELU)vs › | $50.66M | 79.62% | 74.20% | 42.17% | 48.15% |
| Clene Inc. (CLNN)vs › | $50.54M | 78.50% | 79.02% | 83.51% | 77.08% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.45M | N/A | 50.00% | 25.00% | 16.67% |
| Microbot Medical Inc. (MBOT)vs › | $50.08M | 0.00% | 0.00% | 0.00% | 0.00% |
| INmune Bio, Inc. (INMB)vs › | $50.51M | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
44.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 90.57% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
